MediciNova CEO issues shareholder update on company developments and outlook. CEO shareholder update provides strategic context but lacks major new catalysts or financial shifts.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 51.00 | 40.36 | 30.81 | 25.42 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 51.17 | 41.07 | 30.99 | 25.92 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.00 | 1.10 | 0.63 | 0.95 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | 1.89 |
| 3.28 | 2.96 | 3.80 | 2.96 |
| 10y | 5y | 3y | |
| Sales | — | — | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.19 | 0.46 | — | — |
—
|
| ’25 | — | 0.13 | 0.12 | 0.15 |
0.41
|
| ’23 | — | — | 1.00 | — |
1.00
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (3.47) | (1.92) | — | — |
—
|
| ’25 | (3.78) | (2.31) | (1.70) | (2.02) |
(9.81)
|
| ’24 | (3.87) | (2.81) | (2.03) | (1.93) |
(10.64)
|
| ’23 | (3.18) | (2.38) | (1.37) | (0.50) |
(7.43)
|
| ’22 | (3.73) | (2.46) | (2.72) | (4.01) |
(12.91)
|
| ’21 | (3.85) | 1.13 | (3.02) | (3.64) |
(9.38)
|
| ’20 | (2.88) | (2.09) | (3.91) | (1.95) |
(10.83)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (3.48) | (1.92) | — | — |
—
|
| ’25 | (3.78) | (2.31) | (1.71) | (2.02) |
(9.81)
|
| ’24 | (3.87) | (2.81) | (2.03) | (1.93) |
(10.64)
|
| ’23 | (3.18) | (2.40) | (1.37) | (0.50) |
(7.45)
|
| ’22 | (3.73) | (2.46) | (2.72) | 15.87 |
6.96
|
| ’21 | (3.85) | 1.10 | (3.02) | (3.64) |
(9.41)
|
| ’20 | (2.88) | (2.09) | (3.91) | (1.98) |
(10.86)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.05) | (0.05) | — | — |
—
|
| ’25 | (0.06) | (0.07) | (0.06) | (0.05) |
(0.24)
|
| ’24 | (0.06) | (0.05) | (0.06) | (0.06) |
(0.23)
|
| ’23 | (0.06) | (0.06) | (0.01) | (0.04) |
(0.17)
|
| ’22 | (0.07) | (0.08) | (0.07) | (0.06) |
(0.29)
|
| ’21 | 0.00 | (0.09) | (0.07) | (0.04) |
(0.21)
|
| ’20 | (0.06) | (0.10) | (0.08) | (0.07) |
(0.31)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 1.95 | 1.38 | 1.12 | 1.13 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.18 | 2.66 | 2.55 | 2.20 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | — | ‡‡‡‡ | 13 | 13 | 13 | 6 | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | — | ‡‡‡‡‡ | 0.00 | 0.08 | 0.00 | 0.07 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | ‡‡‡‡‡ | — | 1.00 | — | 0.41 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 100.00% | — | 7.59% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.07) | (8.57) | (11.04) | (11.99) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 0.00% | (856.85%) | 0.00% | (2,927.02%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.07) | (8.57) | (11.05) | (12.00) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.02 | 0.02 | 0.02 | 0.02 | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.02 | 0.00 | 0.01 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.29) | (0.17) | (0.23) | (0.24) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.26) | (0.15) | (0.22) | (0.20) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.41 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.14 | (0.15) | (0.22) | (0.20) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.43 | 1.27 | 1.07 | 0.85 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 49.05 | 49.05 | 49.05 | 49.06 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | ‡‡‡ | — | 0.00 | — | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | — | 7.33 | — | 45.60 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | — | 1.30 | — | 1.55 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | — | 2.77 | — | 24.22 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | ‡‡‡‡‡ | — | 2.46 | — | (3.48) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.91) | (7.43) | (10.64) | (9.81) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 19.87 | (0.02) | 0.00 | 0.00 | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.96 | (7.45) | (10.64) | (9.81) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 55.80 | 47.90 | 38.12 | 27.19 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.68 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (57.81) | (51.00) | (40.36) | (30.81) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 70.24 | 62.38 | 52.50 | 41.59 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (17.42%) | (12.21%) | (18.09%) | (23.65%) | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (73.52%) | (54.38%) | (65.23%) | (77.01%) | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (18.28%) | (12.93%) | (19.24%) | (25.50%) | — | — | — |
ROE
|
MediciNova (MNOV), a cash-rich clinical-stage biotech chasing breakthroughs in ALS, glioblastoma, and asthma, exemplifies the high-stakes gamble of development-stage drugmakers: a stock crushed 68-75% over the past decade amid ballooning losses and negligible revenue, yet buoyed by a fortress-like $40 million net cash pile funding a 3.5-year runway without dilution. Sporadic milestones from lead asset MN-166 (ibudilast)—like 2021’s $4 million licensing windfall and positive ALS Phase 2b data—sparked fleeting rallies, but persistent negative EPS (-0.23 in 2024), cash burn, and trial delays have eroded shares to a $1.12-$2.55 range, decoupling from fundamentals while analysts flash eye-popping targets implying 508-643% upside from $1.48.
Despite the optimism, cracks loom large: no insider buys amid zero transactions signal caution, forecasts predict revenue cratering 85% and losses swelling to $34 million by 2027 on Phase 3 costs, with ROE tanking to -19% and a 90% ALS trial failure rate lurking. Yet, this binary lottery—COMBAT-ALS topline due 2026—could unleash 4-8x returns on success, per analogs, with Monte Carlo models pegging 474% upside at the 75th percentile versus a $0.80 cash floor. MNOV’s asymmetry tempts speculators, but demands steel nerves against execution risks and dilution threats.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.